Bio-Pharm Archives - 코메디닷컴

Healthcare Index Up 31%, but GC Pharma and Yuhan Corp. Move Backward

Share prices of pharmaceutical and biotech companies rose sharply this year, driven largely by biotech firms leveraging platform technologies to secure major licensing deals with global pharmaceutical companies. In contrast,…

Park Pyeongtak

2025-12-29

As Parliament Drags Its Feet, Kwangdong Pharmaceutical, Daewoong, and Humedix Swap Treasury Shares

As a proposed amendment to the Commercial Act mandating the cancellation of treasury shares has been submitted to the National Assembly, pharmaceutical and biotech companies have begun moving swiftly. Beyond…

Park Pyeongtak

2025-12-24

[Exclusive] Oscotec Minority Shareholders Demand Right to Nominate Two Directors

Minority shareholders of Oscotec Inc. have been confirmed to have submitted a set of demands to the company seeking broad involvement in corporate management. The core of the proposal includes…

Park Pyeongtak

2025-12-23

Oscotec and ADEL License Alzheimer’s Drug Candidate to Sanofi in KRW 1.5 Trillion Deal

Oscotec Inc. announced on the 16th that it has licensed an Alzheimer’s disease drug candidate jointly researched and developed with ADEL Inc. to global healthcare company Sanofi in a deal…

Park Pyeongtak

2025-12-16

Quantum-Coupled Q-Pharmulator Aims to Identify Drug Candidates with Reduced Cardiac and Liver Toxicity

On the 5th of last week, at the “2025 Korea Tech Festival” held at COEX in Seoul, one session in particular drew strong attention from pharmaceutical and biotech industry professionals.…

syoon

2025-12-12

Alteogen Moves Toward the Main Board…Shareholders Approve “KOSPI Transfer Listing”

Alteogen, the No. 1 company on KOSDAQ by market capitalization, is set to move to Korea’s main bourse, the KOSPI market. This marks the second major biotech transfer listing following…

Park Pyeongtak

2025-12-08

Global Pharma’s Repeated Alzheimer’s Drug Failures Open New Opportunities for Korean Biotechs

As global pharmaceutical giants such as Johnson & Johnson (J&J) and Novo Nordisk face setbacks in developing Alzheimer’s treatments, Korean companies that have already progressed into clinical stages are drawing…

Park Pyeongtak

2025-12-02

Samsung Biologics Secures Land Equivalent to 26 Soccer Fields in Songdo…To Produce ADCs and Other Advanced Therapies

Samsung Biologics is significantly expanding its handling of next-generation therapeutics as it strengthens the growth engine of its contract development and manufacturing organization (CDMO) business. To achieve this, the company…

Park Pyeongtak

2025-12-01

Celltrion: “Zympentra Shows Consistent Therapeutic Effect Across All Intestinal Inflammatory Sites”

Celltrion announced that its autoimmune disease therapy Zympentra—the U.S. brand name for the subcutaneous (SC) formulation of Remsima (active ingredient: infliximab)—demonstrated significant therapeutic effects regardless of the location of intestinal…

Park Pyeongtak

2025-11-26

HK inno.N to Surpass 1Trillion won in Sales Despite Slump in “Condition” Brand

Despite the ongoing slump of its flagship hangover-relief drink “Condition,” HK inno.N is expected to surpass ₩1 trillion in annual revenue this year. Although the company has been hit by…

Park Pyeongtak

2025-11-25